194 related articles for article (PubMed ID: 11988539)
1. Pediatric drug trials. Challenge to FDA's authority may end up giving it more.
Marshall E
Science; 2002 May; 296(5569):820-1. PubMed ID: 11988539
[No Abstract] [Full Text] [Related]
2. America's other drug problem: how the drug industry distorts medicine and politics.
Relman AS; Angell M
New Repub; 2002 Dec; 227(25):27-41. PubMed ID: 12561803
[No Abstract] [Full Text] [Related]
3. The ODAC Chronicles: Part 3. The FDA's philosophy and process for cancer drug evaluation and approval.
Grillo-López AJ
Expert Rev Anticancer Ther; 2005 Feb; 5(1):1-5. PubMed ID: 15757431
[No Abstract] [Full Text] [Related]
4. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
O'Reilly JT
Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
[No Abstract] [Full Text] [Related]
5. The FDA's new oncology office.
Pazdur R
Clin Adv Hematol Oncol; 2005 Aug; 3(8):612-3. PubMed ID: 16167044
[No Abstract] [Full Text] [Related]
6. The FDA's drug review process: ensuring drugs are safe and effective.
Meadows M
FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
[No Abstract] [Full Text] [Related]
7. Pediatric study of medicines becomes mandatory.
Bonetta L
Nat Med; 2000 Oct; 6(10):1069. PubMed ID: 11017118
[No Abstract] [Full Text] [Related]
8. Women's health advocates dismayed at FDA's Plan B decision.
Ready T
Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017
[No Abstract] [Full Text] [Related]
9. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
Merkatz RB
J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
[No Abstract] [Full Text] [Related]
10. FDA's emergency research rule: an inch given, a yard taken.
Gillenwater GE
Food Drug Law J; 2008; 63(1):217-56. PubMed ID: 18561460
[No Abstract] [Full Text] [Related]
11. FDA reform: new Senate bill. Food and Drug Administration.
James JS
AIDS Treat News; 1995 Nov; (no 235):7-8. PubMed ID: 11363048
[TBL] [Abstract][Full Text] [Related]
12. Prescribing medications in pediatrics: concerns regarding FDA approval and pharmacokinetics.
Novak E; Allen PJ
Pediatr Nurs; 2007; 33(1):64-70. PubMed ID: 17411005
[TBL] [Abstract][Full Text] [Related]
13. FDA's monitoring of clinical trials.
Sloboda W; Currier C
Psychopharmacol Bull; 1985; 21(1):105-6. PubMed ID: 3983331
[No Abstract] [Full Text] [Related]
14. Pediatric clinical trials: shall we take a lead?
Schreiner MS; Greeley WJ
Anesth Analg; 2002 Jan; 94(1):1-3. PubMed ID: 11772791
[No Abstract] [Full Text] [Related]
15. DSHEA provisions confine FDA's authority to issue regulations that concern allegedly adulterated dietary supplements.
McNamara SH; Siegner AW; Phelps EP
Food Drug Law J; 1999; 54(4):595-8. PubMed ID: 11824456
[No Abstract] [Full Text] [Related]
16. Pediatric drug development in anesthesiology: an FDA perspective.
Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA
Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624
[No Abstract] [Full Text] [Related]
17. The FDA's definitions, designations, and drug approvals: too daring?
The Lancet Haematology
Lancet Haematol; 2018 Aug; 5(8):e321. PubMed ID: 30075830
[No Abstract] [Full Text] [Related]
18. Promoting, improving and accelerating the drug development and approval processes.
Graul AI
Drug News Perspect; 2009; 22(1):30-8. PubMed ID: 19209297
[TBL] [Abstract][Full Text] [Related]
19. The FDA and drug safety: a proposal for sweeping changes.
Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
[TBL] [Abstract][Full Text] [Related]
20. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
